Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
This study is ongoing, but not recruiting participants.
Study NCT00644189 Information provided by Massachusetts General Hospital
First Received on March 24, 2008. Last Updated on March 11, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Follicular Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Small Lymphocytic Lymphoma
Lymphoplasmacytic Lymphoma
Diffuse Large B-cell Lymphoma
Peripheral T-cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Anaplastic Large-cell Lymphoma
Additional conditions recognized in this trial
Immunoblastic Lymphadenopathy
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma
Lymphoma, B-Cell
Lymphoma, B-Cell, Marginal Zone
Lymphoma, Follicular
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Mantle-Cell
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Waldenstrom Macroglobulinemia
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Leukemia
Leukemia, B-Cell
Leukemia, Lymphoid
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Plasma Cell
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
Clofarabine
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Massachusetts General Hospital
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Genzyme
Back to top of Main Content
